The purpose of this study was to perform a comparative analysis of Rotavirus A (RVA) G and P genotypes circulating in the Brazilian Mid-West in the period 1986-2015. Seven studies conducted from 1986 to 2009 were included, as well as fecal samples obtained in the period 2014-2015. RVA was screened by ELISA and/or PAGE; genotyping by conventional RT-PCR and/or genomic sequencing. A temporal variation in the predominance of G genotypes mainly G1 and G2 with G9 and G12 emergence was observed. Even with vaccination, RVA continues to circulate in the population, requiring continuous virus monitoring.
Worldwide G1 and P [8] have been the predominant genotypes (Santos & Hoshino, 2005) , being replaced at regular intervals, especially by G2 and P [4] ( Dóró et al., 2014) , as well as other emerging genotypes such as G5 and G9 (Santos & Hoshino, 2005) . Many studies of the genotypic profile of RVA, in the Brazilian Mid-West, have been conducted since 1986, detecting the occurrence of distinct G and P genotypes with changes over time, notably G1P [8] , G2P [4] and G9P [8] Considering that the pediatric population in Brazil has access to both RVA vaccines, this study presents the genotypic variability of RVA in the region, in the pre-and post-vaccine periods.
In order to analyze the circulation of G and P genotypes in the Brazilian Mid-West, data was compared from studies conducted in the Mid-West in the pre-vaccine period (Cardoso et (Cardoso et al., 2000) and children that attended day-care centers (Borges et al., 2011) .
The study conducted during 2014-2015 included samples obtained from children under five years of age, with or without AGE symptoms hospitalized in a child-care referral hospital in the state of Goiás (Hospital Materno Infantil de Goiânia). One fecal sample was obtained from each child after the parent or legal guardian signed the written consent form.
This study was approved by the Ethics Committee of Research in the Hospital das Clínicas of the Universidade Federal de Goiás, (Protocol: 19948113.6.0000.5078).
All the samples obtained in the period 1986-2009 were screened by Enzyme-Linked Immunosorbent Assay (ELISA), according to the manufacturer's instructions and/or Polyacrylamide Gel Electrophoresis (PAGE) using protocols previously described (Pereira et al., 1983) .
RVA positive samples obtained in this period underwent G and P genomic amplification by conventional RT-PCR. The dsRNA was extracted using Trizol reagent (Invitrogen TM /Life Technologies, Foster City, USA), following the manufacturer's instructions. The reverse transcription of dsRNA and the amplification reaction were performed using specific primer pairs for the VP7 and VP4 encoding genes, previously described (Gouvea et al., 1990 , Gentsch et al., 1992 . Negative (sterile water) and positive (RVA positive samples) controls were also included in each run.
The amplification products were analyzed in 1.5% agarose gel, 0.5X TBE buffer (Tris-HCl-Borate-EDTA) with ethidium bromide staining, compared to the 100 bp ladder (Invitrogen TM /Life Technologies, Foster City, USA), and visualized under UV light (Vilbert Loumart). Fragments with an expected size of 876 and 1.062 bp (VP4 and VP7, respectively) were considered positive. All procedures were conducted in the proper environment in order to avoid contamination.
For the samples obtained in 2014-2015, RVA screening was performed using PAGE following a previously described protocol (Pereira et al., 1983) . RVA positive samples underwent genomic sequencing of genes encoding VP7 (G) and VP4 (P) proteins using the same primers and conditions of conventional RT-PCR (Gouvea et al., 1990 , Gentsch et al., 1992 .
The genomic sequencing was performed using the BigDye Terminator kit (Applied Biosystems TM , USA) in automatic sequencer (ABIPrism 3130, Applied Biosystems TM , USA). The genotyping was performed by comparison with sequences deposited in the National Center for Biotechnology Information (NCBI) (https://www.ncbi.nlm.nih.gov).
RVA G and P genotypes were detected in previous studies conducted in the Brazilian Mid-West, in 1986-2009, when G1 and P [8] genotypes proved predominant among 474 RVA positive samples with positivity rate ranging from 3.6 to 41.8% (Table 1) .
Analyses regarding the collection period showed that in the prevaccine period, G2 predominated in the years 1986-1995 and after that, G1 emerged. G5 was only detected in 1986-1995, and G9 emerged in 1998. Also P [8] proved predominant in all studies and two P [9] samples were detected in 2005. In the post-vaccine period, G2 and P [4] were predominated until 2009.
In 146 samples with G and P combination, G1P [8] proved the most frequent in the pre-vaccine period and after that G2P [4] samples emerged in the post-vaccine period ( Table 2) . In the study conducted in 2014-2015, in which 335 fecal samples were analyzed, 134 were obtained from children with AGE and 201 from children without AGE symptoms. Nine samples (2.6%) were RVA positive; eight were from children with AGE and one sample from a child without AGE symptoms. From the eight samples from children with AGE, four were G12P [8] , one was P [8] , one G12 and the other two were non-typeable for G or P. The positive sample from the child without AGE symptoms was P [8] and nontypeable G.
RVA vaccination has resulted in an important reduction in the number of AGE cases and disease severity, and consequent hospitalization, around the world (Kollaritsch et al., 2015) . This situation has also been documented in Brazil, including the Mid-West Region, where studies during the pre-vaccine period showed detection rates of up to 37.2% (Cardoso et It is noteworthy that lower positivity rates were observed in the study performed in 1986-1995 (Cardoso et al., 2000) with children with and without AGE and in the study performed in 2008 (Borges et al., 2011) which included children without AGE, performed in the pre-and post-vaccine periods, respectively.
In the 2009-2010 study (Munford et al., 2009 ) conducted with hospitalized children with AGE, including samples from both periods, a higher detection rate (41.8%) was observed. This data contrasts with the literature and also the results from the study conducted in the period 2014-2015 when 2.6% positivity for RVA was observed, even considering only the AGE population (6.0%).
It was supposed that this study (2014-1015) would be limited due to the use of a single technique (PAGE) to screen RVA. Although this methodology presents good specificity, its sensitivity is lower than other techniques like ELISA. Even so, the reduction of RVA detection may be related to vaccine benefits in the Mid-West Region.
Regarding G and P combinations, a predominance of G1P [8] These data indicate a regular tendency to fluctuation in RVA G and P genotypes in the human population. This situation cannot be solely attributed to vaccination since RVA may mutate over relatively short period of time resulting in shifts in the circulation of predominant genotypes over time.
Therefore, despite the benefits of vaccines, considering the reduction of RVA positivity and hospitalization cases of AGE, the virus continues to circulate, with the same vaccine genotypes or in a different one, such as G12P [8] . Therefore, continuous monitoring of RVA samples circulating among the human population remains important.
Finally, the continuity of studies that focus on RVA dynamics in the human population may help to predict changes in the genotypic profile of the circulating samples and in determining preventive measures such as the development of vaccines from the predominant genotypes over time.
